We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Different Clinical Hematology Lab Configurations Compared

By LabMedica International staff writers
Posted on 22 Apr 2019
Print article
Image: The CellaVision DM96 digital cell morphology system is designed to automate the time-consuming, manual effort associated with traditional microscopy (Photo courtesy of CellaVision).
Image: The CellaVision DM96 digital cell morphology system is designed to automate the time-consuming, manual effort associated with traditional microscopy (Photo courtesy of CellaVision).
Automated hematology analyzers are key clinical laboratory instruments that measure blood counts, identify subsets of nucleated blood cells, and flag specimens for further manual analysis. These analyzers range in price and functionality.

Examination of stained blood smears may be performed with a microscope or may be semi-automated with digital image analysis systems. The performance and costs of currently available analysis configurations with special focus on a proposed alternative using a minimal hematology analyzer plus a digital imaging device, allowing for remote oversight and interpretation has been compared.

Medical Laboratory scientists at the University of California, San Diego (La Jolla, CA, USA) and their colleagues used patient samples with orders for complete blood counts (CBCs) with white blood cell (WBC) differentials. During a 6-week period, a total of 206 blood samples were selected to represent a variety of clinical conditions, including samples with no abnormalities. The team wanted to determine whether low-volume laboratories might realize savings while gaining function by substituting commonly used configurations with a proposed alternative.

The investigators evaluated the performance of the proposed alternative configuration, blood counts with automated differentials produced by a Sysmex XE5000 (complete blood count reference method) were compared with cell counts from the Sysmex pocH-100i, CellaVision DM96 preclassified differentials, and DM96 reclassified differentials (differential reference method) by using standard regression analyses, 95% CIs, and truth tables. Financial cost modeling used staffing practices, test volumes, and smear production rates observed at remote clinics performing on-site hematology analysis.

The team reported that differential blood count parameters showed excellent correlation between the XE5000 and preclassification DM96. For blasts/abnormal cells, immature granulocytes, and nucleated red blood cells, the DM96 showed higher sensitivity and similar specificity to the XE5000. Cost modeling revealed that decreased personnel costs through remote monitoring of results facilitated by the DM96 would lead to lower operational costs relative to more conventional analysis configurations.

The authors concluded that the adoption of hematology analysis configurations including the CellaVision system at clinical sites with low to moderate daily testing volume (i.e., fewer than 100 tests per day) will likely lead to decreased costs, more efficient personnel utilization, and improved overall service (for example, decreased turnaround time and increased accuracy) as compared to configurations using either simple or complex hematology analyzers. The study was published on April 10, 2019, in the journal Archives of Pathology & Laboratory Medicine.

Related Links:
University of California, San Diego

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.